FIDURA Private Equity Fonds
- Land: Deutschland
Nachricht vom 04.11.2013 | 14:00
FIDURA Private Equity Fonds a new lead investor at m2p-labs // Investment in leading manufacturer of microbioreactors
FIDURA Private Equity Fonds / Key word(s): Funds
Founded in 2005, m2p-labs GmbH successfully closed its financing round with FIDURA Private Equity Fonds as a new lead investor. Through a capital increase with the participation of seed investors such as the High-Tech-Gründerfonds as the biggest co-investor, FIDURA-Fonds acquired a total stake of 27.61% of m2p-labs GmbH. Their unique technology, a portfolio of renowned international customers as well as the strong growth potential of the company were key criteria for FIDURA-Fonds in opting to invest in the company.
m2p-labs GmbH, based in Baesweiler near Aachen, is a leading global manufacturer of microbioreactors. The company is engaged in the development and sales of lab analysis systems (microbioreactors) to carry out what are known as high throughput test series in the field of cellular screening and bioprocess development. 'm2p' stands for 'from microreactor to process'.
Using optical measuring technology combined with miniaturization and intelligent analysis methods, the company was able to create an innovative system (BioLector(R) technology) that provides the user with important information in a non-invasive way and with online monitoringduring the process of fermentation (biomass, product concentration, fluorescence as well as pH-value and dissolved oxygen); this information is provided already at a very early stage of development in microscale and thus significantly reduces the use of large laboratory fermenters. In addition, the patented BioLector(R) technology allows relevant process-related parameters (e.g. oxygen mass transfer, mixing time) to be set precisely, also in microscale, facilitating later scale-up. The technology is suitable for diverse screening tasks such as strain selection, promoter characterization, optimization of culture media and bioprocess development. Because relevant process information is received quickly while at the same time high-throughput is possible (high-content screening), different clones, media and process conditions can easily be tested in parallel - the user is thus able to efficiently develop a multitude of bioprocesses and products in a much shorter time to market.
The company is serving the fast growing bioeconomy with its platform technology. Thus, m2p-labs is specifically targeting customers from the pharmaceutical, chemical and biotechnological industries who wish to organize their screening and their biotechnological processes more efficiently and to automate them further. Fields of application include cellular and microbial screening, synthetic and systems biology, proteomics (high throughput protein expression), optimization of fermentation and characterization of aerobic and anaearobic bioprocesses. The technology of m2p-labs is available to the customer as an instrument system with analysis software for in-house use. In addition, the company generates ongoing revenues by selling unique and patented disposable microplates (FlowerPlate(R)) for use in their systems.
Since its foundation, m2p-labs has continuously pursued a growth course and has been able to establish itself in a variety of market sectors based on its unique patented products. Renowned pharmaceutical and chemical companies and well-known universities (ETH Zürich, RWTH Aachen, University College London and Imperial College London) and research institutions such as the Jülich Research Centre, to name but a few, can be found on the list of m2p-labs customers.
With the capital invested by FIDURA-Fonds, the company wants to further expand its technological edge with new developments and product improvements, particularly in the field of microscale process control (fed-batch and pH control) and automation of the BioLector(R) technology. Further, the company would like to increase its global sales network, especially in the USA and Asia.
About FIDURA Private Equity Fonds
FIDURA was established in 2001 by experienced entrepreneurs and capital market specialists as an independent consultant and underwriter of private equity. With an investment concept taking into account the special need for security of normal investors and an investment approach geared to the utmost security, FIDURA has deliberately struck out in a new direction. The vision is both to provide access to private equity to normal investors and to medium-sized companies seeking capital. As a lender of capital, a coach and sparring partner, the experienced management of FIDURA accompanies small and medium-sized enterprises (SMEs) with revenues above 1 million euros in the implementation of their growth plans. With the four funds set up to date, the issuing house has been able to place a total volume of approx. 110 million euros with more than 4000 investors to date. FIDURA is therefore one of the leading providers of direct-investing, closed-end private equity retail funds in Germany.
FIDURA Private Equity Fonds
Dipl.- Ing. Ingrid Weil
Telefon: +49 (0)89 / 238898-15
Telefax: +49 (0)89 / 238898-29
End of financial news
04.11.2013 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
FIDURA Private Equity Fonds a new lead investo ...
Trotz herausforderndem Marktumfeld: FIDURA hat ...
Neue Regeln für die Vermittlung von Finanzprod ...
FIDURA bringt den vierten direkt investierende ...
FIDURA zieht positive Bilanz für 2011: Portfol ...
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
28. November 08:00 E-Mobilität Batterie Index: Unaufhaltsam
28. November 08:19 DAX-Wochenausblick: Omikron verdirbt die Jahresendrally – oder?
28. November 08:30 TSI USA: 100 Prozent Plus? Keine Besonderheit!
28. November 09:29 Mit System zu den Top-Performern wie Tesla oder Nvidia
28. November 10:00 Biotech-Kursexplosion voraus – dieser Hot-Stock bläst jetzt zum ...
Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten
26. November 2021